Graft Versus Host Disease

Graft Versus Host Disease (GVHD): Symptoms, Causes, Types, Diagnosis, and Treatments

Graft versus host disease (GVHD) is a serious and potentially life-threatening complication that can occur after a stem cell or bone marrow transplant. While the transplant aims to cure various blood-related cancers and diseases, it can sometimes lead to unintended consequences. GVHD occurs when the transplanted immune cells (the graft) recognize the recipient’s body (the host) as foreign and begin to attack healthy tissues. Understanding this condition is crucial for both healthcare professionals and patients undergoing transplantation.

In this comprehensive guide, we delve into the symptoms, causes, types, diagnosis, and treatment of GVHD. This article is a complete resource for individuals seeking reliable and detailed information about GVHD.

---

What is Graft Versus Host Disease?

Graft Versus Host Disease is an immune-mediated condition. It typically occurs after an allogeneic stem cell transplant, where the stem cells come from a donor rather than the patient themselves. The donor’s immune cells can attack the host’s body, mistaking it for a threat.

Graft Versus Host Disease can affect various organs and tissues, including the skin, liver, gastrointestinal tract, lungs, and eyes. The severity of GVHD can range from mild to severe and can greatly impact the success and recovery process after transplantation.

---

Causes of GVHD

GVHD is caused by immune incompatibility between the donor and recipient. Here’s a deeper look into the underlying causes:

1. Mismatch in Human Leukocyte Antigens (HLA)

HLA are proteins found on most cells in the body. They help the immune system recognize which cells belong in the body and which do not. A mismatch in HLA between donor and recipient is a major risk factor for GVHD.

2. Donor T-cell Activation

T-cells from the donor are introduced during the transplant. If they recognize the host’s cells as foreign, they initiate an immune response, leading to tissue damage.

3. Recipient’s Condition

The more weakened or immunocompromised the recipient is at the time of transplant, the more susceptible they may be to developing GVHD.

4. Age and Gender Disparity

Older age of the donor or recipient and gender mismatches (e.g., male recipient with female donor) can increase GVHD risk.

5. Source of Stem Cells

Stem cells may be derived from peripheral blood, bone marrow, or umbilical cord blood. Each has varying risks associated with GVHD.

---

Types of Graft Versus Host Disease

Graft Versus Host Disease is generally classified into two types based on the time of onset:

1. Acute Graft Versus Host Disease

Acute GVHD typically develops within the first 100 days after the transplant. It often affects:

• Skin – Rashes, redness, or peeling.
• Liver – Elevated liver enzymes, jaundice.
• Gastrointestinal tract – Nausea, vomiting, abdominal pain, diarrhea.

Grading of Acute Graft Versus Host Disease
Acute GVHD is graded from I to IV based on severity:

• Grade I: Mild skin rash.
• Grade II: Moderate skin rash with mild liver or gut involvement.
• Grade III: Severe symptoms, including significant liver and gut involvement.
• Grade IV: Life-threatening multi-organ damage.

2. Chronic GVHD

Chronic Graft Versus Host Disease can begin after 100 days post-transplant and may persist for months or years. It can affect a broader range of organs and mimic autoimmune diseases.

Symptoms include:

• Skin thickening and dryness
• Dry eyes and mouth
• Hair loss
• Joint stiffness
• Lung dysfunction (bronchiolitis obliterans)

---

Symptoms of GVHD

The symptoms of Graft Versus Host Disease vary depending on the type and severity. Here’s a breakdown:

A. Skin

• Red rash (commonly on the palms and soles)
• Peeling or blistering skin
• Hyperpigmentation or hypopigmentation
• Itching or burning sensation

B. Gastrointestinal Tract

• Severe diarrhea (watery or bloody)
• Abdominal cramps and pain
• Nausea and vomiting
• Poor appetite and weight loss

C. Liver

• Elevated bilirubin levels
• Jaundice (yellowing of the skin and eyes)
• Abnormal liver enzymes

D. Eyes

• Dryness and irritation
• Sensitivity to light
• Blurred vision

E. Mouth

• Dry mouth
• Ulcers
• White patches
• Pain while eating or swallowing

F. Lungs

• Shortness of breath
• Dry cough
• Reduced oxygen levels

G. Other Symptoms

• Fatigue
• Muscle weakness
• Infections due to immunosuppression

---

Diagnosis of GVHD

Diagnosing Graft Versus Host Disease involves a combination of clinical evaluation, laboratory tests, imaging studies, and biopsy procedures.

1. Medical History and Physical Examination

Physicians look for symptoms such as rash, diarrhea, or jaundice in post-transplant patients.

2. Blood Tests

• Liver function tests
• Complete blood count (CBC)
• Inflammatory markers

3. Biopsies

Skin, liver, or gut biopsy may be performed to confirm the diagnosis and rule out infections or other conditions.

4. Endoscopy and Colonoscopy

Used to examine the gastrointestinal tract if gut GVHD is suspected.

5. Pulmonary Function Tests

To assess lung involvement in chronic GVHD.

---

Risk Factors for GVHD

While Graft Versus Host Disease cannot be entirely predicted, several factors increase the likelihood of its occurrence:

• Partial HLA mismatch between donor and recipient
• Older age of donor or recipient
• Gender mismatch (especially female donor to male recipient)
• Use of peripheral blood stem cells
• Intensity of the conditioning regimen
• Previous history of acute GVHD

---

Prevention of GVHD

Prevention focuses on minimizing immune system reactions and includes:

1. HLA Matching

Ensuring the closest possible HLA match between donor and recipient significantly reduces risk.

2. Immunosuppressive Therapy

Drugs like cyclosporine, tacrolimus, and methotrexate are used before and after transplant to suppress the immune system.

3. T-cell Depletion

Removing T-cells from the donor graft reduces the risk but may also compromise the graft-versus-leukemia effect.

4. Post-Transplant Cyclophosphamide

A newer approach used in haploidentical transplants to selectively target reactive T-cells.

---

Treatment of GVHD

Treatment depends on the type (acute or chronic), severity, and the organs involved.

A. Corticosteroids

First-line therapy, particularly for moderate to severe GVHD. Prednisone or methylprednisolone is commonly used.

B. Calcineurin Inhibitors

Tacrolimus and cyclosporine are standard immunosuppressants used in GVHD treatment.

C. Monoclonal Antibodies

• Ruxolitinib (Jakafi): JAK1/2 inhibitor approved for steroid-refractory GVHD.
• Infliximab and Etanercept: Target tumor necrosis factor-alpha (TNF-α).
• Rituximab: Used in B-cell mediated chronic GVHD.

D. Extracorporeal Photopheresis (ECP)

A procedure that involves treating the patient’s blood with ultraviolet light to modulate immune responses.

E. Supportive Care

• Nutritional support for GI involvement
• Skin creams and moisturizers
• Eye drops for dryness
• Pain management
• Infection control

F. Stem Cell Boost or Donor Lymphocyte Infusion (DLI)

In selected cases, donor cells are reintroduced to enhance immune reconstitution without exacerbating GVHD.

---

Prognosis and Long-Term Outlook

The outcome of Graft Versus Host Disease depends on several factors:

• Early detection and prompt treatment improve outcomes.
• Mild to moderate GVHD may be managed effectively.
• Severe or steroid-refractory GVHD is associated with a higher mortality rate.

With ongoing research and newer treatments, survival and quality of life are improving. Chronic GVHD requires long-term care and multidisciplinary management.

---

Living with GVHD

Patients with chronic Graft Versus Host Disease often need ongoing care from dermatologists, gastroenterologists, ophthalmologists, and physical therapists.

Tips for Daily Management:

• Adhere strictly to medication regimens.
• Practice good hygiene and avoid infection sources.
• Maintain a nutritious, easily digestible diet.
• Use sunscreen to protect sensitive skin.
• Monitor symptoms and communicate with healthcare providers regularly.

---

Research and Future Directions

Advancements in genomics, immunotherapy, and cell engineering are opening new doors for GVHD treatment:

• Biomarker discovery for earlier and more accurate diagnosis
• Cellular therapies, including mesenchymal stem cells, show promise
• CAR-T cell therapy modification to reduce GVHD risk
• Personalized medicine approaches for individualized risk stratification

Clinical trials continue to investigate novel agents and strategies that could transform GVHD management in the near future.

---

Conclusion

Graft versus host disease is a complex and challenging complication of stem cell transplantation. While it poses serious risks, timely diagnosis, appropriate treatment, and preventative strategies can greatly improve outcomes. With evolving research and a growing understanding of immunology, the future for GVHD patients is becoming increasingly hopeful.

If you or a loved one is undergoing or planning a stem cell transplant, being informed about GVHD is an essential part of the journey. Early intervention and regular follow-ups with your healthcare team can make a significant difference.

Frequently Asked Questions (FAQs) About Graft Versus Host Disease

For more details keep visiting our Website & Facebook Page.